Full Fed. Circ. Urged To Rethink Corcept Patent Loss
Corcept Therapeutics Inc. wants the Federal Circuit to rethink a panel's refusal to revive its suit accusing Teva Pharmaceuticals USA Inc. of patent infringement over its production of a generic version...To view the full article, register now.
Already a subscriber? Click here to view full article